Heat Biologics Stock News

DURHAM, NC / ACCESSWIRE / May 15, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic .

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that the company will present data from its expanding oncology pipeline...

The American Society of Clinical Oncology released abstracts of the papers set to be presented at its coming meeting. Analysts and investors are combing through the documents for key developments.

Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients DURHAM, NC / ACCESSWI

Foundation Medicine and Collaborators to Share New Data at ASCO20 Showcasing the Importance of CGP in Informing Cancer Clinical Decision-Making

- Results from two studies of BAVENCIO® to be featured in ASCO press briefing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d)...

NovoCure is developing and commercialising a novel form of cancer therapy treatment - Tumor Treating Fields - which uses electric fields to disrupt solid tumor

The

NanoString Highlights Recent Publications that Demonstrate the Performance of the GeoMx DSP.

Eli Lilly's Retevmo gets FDA approval. Arcturus announces positive preclinical data for Covid-19. Quidel's antigen test kit gets FDA approval.

DURHAM, NC / ACCESSWIRE / May 11, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod